CN1853722A - 预防由抗精神病药物引起的体重增加的方法 - Google Patents

预防由抗精神病药物引起的体重增加的方法 Download PDF

Info

Publication number
CN1853722A
CN1853722A CNA2005101236436A CN200510123643A CN1853722A CN 1853722 A CN1853722 A CN 1853722A CN A2005101236436 A CNA2005101236436 A CN A2005101236436A CN 200510123643 A CN200510123643 A CN 200510123643A CN 1853722 A CN1853722 A CN 1853722A
Authority
CN
China
Prior art keywords
glucocorticoid receptor
receptor antagonists
purposes
patient
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005101236436A
Other languages
English (en)
Chinese (zh)
Inventor
约琵夫·K·贝拉诺夫
艾伦·F·斯彻特贝格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corcept Therapeutics Inc
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of CN1853722A publication Critical patent/CN1853722A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CNA2005101236436A 2001-07-23 2002-07-22 预防由抗精神病药物引起的体重增加的方法 Pending CN1853722A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30769301P 2001-07-23 2001-07-23
US60/307,693 2001-07-23

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA028166647A Division CN1547473A (zh) 2001-07-23 2002-07-22 预防由抗精神病药物引起的体重增加的方法

Publications (1)

Publication Number Publication Date
CN1853722A true CN1853722A (zh) 2006-11-01

Family

ID=23190816

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2005101236436A Pending CN1853722A (zh) 2001-07-23 2002-07-22 预防由抗精神病药物引起的体重增加的方法
CNA028166647A Pending CN1547473A (zh) 2001-07-23 2002-07-22 预防由抗精神病药物引起的体重增加的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA028166647A Pending CN1547473A (zh) 2001-07-23 2002-07-22 预防由抗精神病药物引起的体重增加的方法

Country Status (20)

Country Link
US (1) US6680310B2 (da)
EP (1) EP1408981B1 (da)
JP (2) JP2004537563A (da)
KR (1) KR20040028942A (da)
CN (2) CN1853722A (da)
AT (1) ATE406166T1 (da)
AU (1) AU2002319665B2 (da)
BR (1) BR0211365A (da)
CA (1) CA2454339C (da)
CY (1) CY1108562T1 (da)
DE (1) DE60228579D1 (da)
DK (1) DK1408981T3 (da)
ES (1) ES2312598T3 (da)
HK (1) HK1061526A1 (da)
IL (1) IL159913A0 (da)
MX (1) MXPA04000692A (da)
NZ (1) NZ530724A (da)
PT (1) PT1408981E (da)
WO (1) WO2003009853A1 (da)
ZA (1) ZA200400444B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE411013T1 (de) * 2001-08-31 2008-10-15 Corcept Therapeutics Inc Verfahren zur hemmung der verschlechterung der kognitiven leistungsfähigkeit bei erwachsenen mit down-syndrom
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
GB0400031D0 (en) 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
US20060211667A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of pregnane steroid derivatives for enhancing physical performance
WO2007067714A2 (en) * 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
US8198305B2 (en) * 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
ES2869172T3 (es) * 2013-11-25 2021-10-25 Corcept Therapeutics Inc Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients
AU2018244928B2 (en) 2017-03-31 2023-10-19 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
US11273166B2 (en) 2017-06-13 2022-03-15 Monash University Methods and compositions for the treatment of obesity
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
BR112021010461A2 (pt) 2018-12-19 2021-08-24 Corcept Therapeutics Incorporated Formulação e dose unitária para administração oral de relacorilante
WO2020172501A1 (en) 2019-02-22 2020-08-27 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
EP3941460A4 (en) * 2019-03-18 2022-12-28 Nieman, Lynnette K. METHOD FOR IMPROVING INSULIN SENSITIVITY
CA3158745A1 (en) 2019-12-11 2021-06-17 Corcept Therapeutics Incorporated Methods of treating antipsychotic-induced weight gain with miricorilant
CN115515569A (zh) 2020-05-06 2022-12-23 科赛普特治疗公司 嘧啶环己基糖皮质激素受体调节剂的制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757400B1 (fr) * 1996-12-19 1999-12-17 Hoechst Marion Roussel Inc Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs
WO1998027986A1 (en) * 1996-12-24 1998-07-02 Zymogenetics, Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
WO1999017779A1 (en) * 1997-10-06 1999-04-15 The Board Of Trustees Of Leland Stanford Jr. University Methods for treating psychosis associated with glucocorticoid related dysfunction
ATE317699T1 (de) 1998-05-15 2006-03-15 Univ Leland Stanford Junior Glucocorticoid receptor antagonisten zur behandlung von demenz
EP1223939A1 (en) * 1999-05-19 2002-07-24 AstraZeneca AB Method of treating weight gain

Also Published As

Publication number Publication date
US6680310B2 (en) 2004-01-20
BR0211365A (pt) 2004-09-21
DE60228579D1 (de) 2008-10-09
ES2312598T3 (es) 2009-03-01
ZA200400444B (en) 2005-03-30
JP2004537563A (ja) 2004-12-16
EP1408981B1 (en) 2008-08-27
EP1408981A4 (en) 2005-06-08
NZ530724A (en) 2005-09-30
WO2003009853A1 (en) 2003-02-06
CA2454339C (en) 2012-01-10
PT1408981E (pt) 2008-12-04
CY1108562T1 (el) 2014-04-09
CN1547473A (zh) 2004-11-17
HK1061526A1 (en) 2004-09-24
ATE406166T1 (de) 2008-09-15
EP1408981A1 (en) 2004-04-21
AU2002319665B2 (en) 2006-09-21
MXPA04000692A (es) 2004-04-21
JP2009102413A (ja) 2009-05-14
CA2454339A1 (en) 2003-02-06
IL159913A0 (en) 2004-06-20
US20030027802A1 (en) 2003-02-06
KR20040028942A (ko) 2004-04-03
DK1408981T3 (da) 2009-01-12

Similar Documents

Publication Publication Date Title
CN1853722A (zh) 预防由抗精神病药物引起的体重增加的方法
CN1820756A (zh) 使用糖皮质激素受体特效拮抗剂治疗压力症的方法
CN100438875C (zh) 抗糖皮质激素在用于提高电休克治疗疗效的药物制备中的用途
CN1599613A (zh) 用于治疗免疫炎性疾病的联合疗法
US20210128584A1 (en) Use of glucocorticoid receptor antagonists for the treatment of amyotrophic lateral sclerosis
AU2002319665A1 (en) Methods for preventing antipsychotic-induced weight gain
US7361646B2 (en) Methods for treating gastroesophageal reflux disease
CN1665515A (zh) 治疗与干扰素α治疗相关的精神病的方法
JP2023052618A (ja) 糖質コルチコイド受容体モジュレータおよびｃｙｐ３ａインヒビタの併用投与
EP2576582A1 (en) Treatment of muscular dystrophy
CN1556708A (zh) 抑制成年唐氏综合症患者认知退化的方法
CN1965840A (zh) 预防由抗精神病药物引起的体重增加的方法
JP2009535430A (ja) Ｉｌ−２を摂取している患者における抑うつを処置するためのグルココルチコイドレセプターｉｉアンタゴニストの使用
CN1527713A (zh) 使用糖皮质激素受体特效拮抗剂治疗谵妄症的方法
US20040229855A1 (en) Antiglucocorticoids for the treatment of postpartum psychosis
CA2532594C (en) Antiglucocorticoids for the treatment of catatonia
CN1853638A (zh) 使用糖皮质激素受体特效拮抗剂治疗谵妄症的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1097752

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20061101

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1097752

Country of ref document: HK